Piqray 200MG Daily Dose and Sudafed PSE
Determining the interaction of Piqray 200MG Daily Dose and Sudafed PSE and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9. MANAGEMENT: Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered. References "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Professional:MONITOR: Coadministration with alpelisib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C9, such as warfarin. The proposed mechanism, based on in vitro data, is increased clearance due to alpelisib-mediated induction of CYP450 2C9.
MANAGEMENT: Patient monitoring is recommended if alpelisib is used concomitantly with drugs that are substrates of CYP450 2C9, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when alpelisib is prescribed in combination with drugs that are CYP450 2C9 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever alpelisib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C9-inducing activity may also be considered.
- "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: alpelisib
Brand name: Piqray
Synonyms: Alpelisib
Generic Name: naproxen / pseudoephedrine
Brand name: Aleve Cold and Sinus, Aleve Sinus & Headache, Aleve-D Sinus & Cold, Sudafed PSE, Aleve-D Cold and Sinus, Sudafed Sinus & Pain 12 Hour, Sinus & Cold-D, Sudafed Sinus 12 Hour Pressure + Pain, Aleve-D Sinus & Headache, Sudafed 12 Hour Pressure + Pain
Synonyms: Naproxen and pseudoephedrine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Piqray 200MG Daily Dose-Sudafed Sinus Nighttime
- Piqray 200MG Daily Dose-Sudal 12 Tannate Chewable
- Piqray 200MG Daily Dose-Sudatex DM
- Piqray 200MG Daily Dose-SudoGest
- Piqray 200MG Daily Dose-SudoGest 12 Hour
- Piqray 200MG Daily Dose-Sudogest PE
- Sudafed PSE-Piqray 250MG Daily Dose
- Sudafed PSE-Piqray 300MG Daily Dose
- Sudafed PSE-Pirbuterol Inhalation
- Sudafed PSE-Pirfenidone
- Sudafed PSE-Pirmella 1/35
- Sudafed PSE-Pirmella 7/7/7